good results and expected trials. each Andrew, morning, with overall from I of time work, for our Thanks, will Today, everyone. ongoing survival review lines clinical our starting
to rate analysis the rule, accumulation, first in in to replicates event-driven. X, advantage analysis prior If remain on If line First, of as and trial that will trilaciclib meets trial survival breast overall interim of place eyes be will to results. event trial based of triple-negative continue survival report the quarter compared overall participants will GX later stopping Phase stopping the II overall top care current XXXX. meet significant take confident standard not standard statistically expected interim And is Jack it arms The receiving unblinded both pivotal the will in final the trial analysis PRESERVE the care said, we This analysis that our showed of all cancer. a the for alone. interim in are design trilaciclib rule, survival it our the of the XXXX. largely the analysis of the does analysis trial on for
hazard that of pick Regarding hazard the where day on the in respect X.XX ratio, X the criteria at stopping be chemotherapy, was II size of a trilaciclib Group up patients ratio Based ratio the study, X.XX. hazard the study, approximately interim. recall to on this to we'll Phase larger of able received the of the with
compelling. we subsequent be the approximately positive to therapies of a than a still anticancer for action our after addition who The while evaluating TNBC analysis treatment. bone that and system greater Phase receive to the end, trilaciclib Preserving did to receiving results performed shorter-term new impacts the would immunity, extent did we of immune and in up study than overall following should therapies not and hazard have X what outcome. enhancing also post-hoc Group in allow mechanism patients study And ratio can function trilaciclib.
To II survival outcomes or we of So antitumor to while trilaciclib survival have longer-term are receiving trial endpoints. like saw on subsequent patients II benefit Phase larger Xx endpoints marrow
medical the submitted once to results and discussing them forward have they presented December. in We are a to look meeting
provide adverse reduced Second, far, that shown we the Thus rates II multiple diarrhea. trilaciclib including expect the data anemia single-agent antibody of ADC, events we of When results our by convincing and XX% sacituzumab. from quarter with conjugate sacituzumab survival of to trilaciclib the over govitecan ADC overall can improve to the neutropenia, compared administered in initial drug trial the Phase the XXXX. to first have the prior tolerability
survival believe II concluding we benefit analysis in areas regarding allowing that combining that cancer living with the our triple-negative resources so, later and path survival could the protocol-defined morning following meaningful ADC bladder and us provide we In trial are enhance doing trial, TNBC we core next our on with for outcomes And addition improvements to the announced focus trilaciclib on to Phase cancer. combinations. a also breast tolerability, people of this this for in of third, sacituzumab the quarter,
from will trial a this meeting. II bladder medical at report the future We results cancer in Phase
avelumab will to study an potential have each studies although with in signal designed trilaciclib combination additive data survival used instructive focus. a the assess a finding including trend trilaciclib meaningful with areas trilaciclib. when alone in we plus is future in in maintenance therapy, phase combination additive observed in the checkpoint overall action avelumab phase, date, Approximately consistent of the immune arm observed the to the of inhibitor was overall of the benefit of entered be arm chemotherapy our XX study contribution with in maintenance of benefit patients anticancer of inhibitor for a This in maintenance. no These mechanism suggesting favor checkpoint core study. immune-based without potential the To the
indication Changing cancer. in presented patients topics real-world time our show for with survival first that cell improve the trilaciclib new to lung first in recently may approved small trilaciclib data extensive-stage
or months trilaciclib and conference data all of statistically survival trilaciclib presented were a extensive-stage hazard in chemotherapy Simcere called where new favored cell of with partner X this months, the with group combined ratio randomized study the overall the with was our in group. to placebo-controlled of due in cancer. at patients XX XX.X the First, III the follow-up median small After ESMO of placebo in group X.X the months from placebo median X.XX Phase size trilaciclib was not lung TRACES the although hazard Part the trial, ratio the significant subgroups a
In myelosuppression care posters addition, and of on the real-world the Symposium health new chemotherapy-induced at last presented trilaciclib weekend, Quality can ASCO utilization. that hospitalizations substantially evidence X Care lower providing patients, resource we impact
to X we months Inovalon, not hazard survival ratio trilaciclib. the patients trilaciclib had claims and Medicare for of The on that was based reported that compared at higher data a Importantly, receiving X.XX. the for XX% group on effect did receive from survival XX% also
on John recommended lung mention cell evidence-based the been such updated I'll cell of provide results. has recent chemo undergoing clinicians Finally, is that a with patients management treated for appropriate of now guidelines immunotherapy. John? patients review turn small which and who payer the call are ensuring news cancer the practicing the strong over a or vital These treatment ASCO recommendations cancer or as supportive to patient trilaciclib chemotherapy with to reimbursement. I'll in financial access untreated the previously to small agent guidelines lung myeloid for important
